Abstract
The identification of genetic markers has revolutionised our assessment of antimalarial drug resistance. Tracking the molecular markers of resistance emerged as a valuable tool over 60 years ago, following the identification of sulphadoxine-pyrimethamine genetic resistance markers, dhfr and dhps. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines were used. PubMed/MEDLINE, Embase, Scopus, Google Scholar and Web of Science were systematically searched to identify studies on antimalarial drug resistance markers in Kenya published in English between 01-Jan-1995 and 31-Oct-2024.
The national analysis showed a regional shift in the timelines from the mutant to wild-type crt genotype and similarly from the mutant (CVIET) to wild-type (CVMNK) microhaplotype, with the Coast occurring earlier in 2002, while Western Kenya the change occurred later in 2008. MDR1 codons 86 and 1246, also genetic markers of chloroquine resistance have shown a full reversion to the wildtype, that was rising since 1994 in the Coast and 2003 in Western Kenya. By the time drug policy changed to SP in 1999 the dhps mutant genotype was already rising from 1996 in the Coast and 1998 from Western Kenya, while the dhfr codon 108 shift to mutant occurred as early as 1988 in the Coastal parasite populations. Emerging WHO validated k13 mutations were first described, P553L, in 2006 in Kisumu.
This aggregation of data across Kenya demonstrates the utility of this scoping review. The compilation and standardization of over 100 studies provides a high-level, structured overview of when and where resistance markers have been surveyed. This establishes a foundational national repository to support strategic surveillance planning by the Kenya NMCP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Calestous Juma Leadership Fellowship, funded by the Bill & Melinda Gates Foundation (INV-036442). RWS is supported as a Wellcome Trust Principal Fellow (#212176). All authors are grateful for the support of the Wellcome Trust to the Kenya Major Overseas Programme (#203077)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data generated or analysed during this study are included in this published article and its supplementary information files.
